The PREVENT trial has met its primary endpoint and was statistically significant. This, says the broker, is a major milestone in the Impedimed's history. The next step is peer review and publication in medical journals.

Unfortunately, due to covid delays this is still a couple of months away. In the meantime, Speculative Buy and 21c target retained.

Sector: Health Care Equipment & Services.

Target price is $0.21.Current Price is $0.18. Difference: $0.03 - (brackets indicate current price is over target). If IPD meets the Morgans target it will return approximately 14% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2021 Acquisdata Pty Ltd., source FN Arena